Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.

doi:10.1158/1078-0432.CCR-20-4879

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2021

Sharma Priyanka, Abramson Vandana G, O'Dea Anne, Nye Lauren, Mayer Ingrid, Pathak Harsh B, Hoffmann Marc, Stecklein Shane R, Elia Manana, Lewis Sharon, Scott Jecinta, De Jong Jilliann A, Wang Yen Y, Yoder Rachel, Schwensen Kelsey, Finke Karissa, Heldstab Jaimie, LaFaver Stephanie, Williamson Stephen K, Phadnis Milind A, Reed Gregory A, Kimler Bruce F, Khan Qamar J, Godwin Andrew K

Abstract excerpt

PURPOSE: PIK3CA mutations are common in breast cancer and promote tumor progression and treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). PATIENTS AND METHODS: Eligible patients had HER2-negative MBC with any number of prior chemotherapies. Phase I was 3+3 dose-escalation design with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Class I Phosphatidylinositol 3-Kinases

Share to Drug Combinations

Share to Neoplasm Metastasis

Share to Paclitaxel

Share to Receptor, ErbB-2

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 33602685
DOI: 10.1158/1078-0432.CCR-20-4879
PMCID: PMC8282704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.PMID 33602685Read ↗

The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancerSemantic proximity Read ↗

A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.Semantic proximity Read ↗

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.Semantic proximity Read ↗

A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.Semantic proximity Read ↗

Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study.Semantic proximity Read ↗

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.Semantic proximity Read ↗

Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumorsSemantic proximity Read ↗

PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance.Semantic proximity Read ↗

Efficacy of PI3K inhibitors in advanced breast cancer.Semantic proximity Read ↗

Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.Semantic proximity Read ↗

Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.Semantic proximity Read ↗

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.